alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 35.2



LOGO

ANNUAL STATEMENT OF COMPLIANCE

OF

LNR PARTNERS, LLC

The undersigned, Job Warshaw, being the President of LNR Partners, LLC (the Special Servicer), as special servicer under the
applicable Pooling and Servicing Agreement for the transactions listed on Schedule I hereto, hereby certifies, subject to any limitations listed on Schedule I hereto, as of the date hereof, on behalf of the Special Servicer, solely in
his capacity as an authorized officer of the Special Servicer and not in his individual capacity, as follows:



| | 1. | A review of the activities performed by the Special Servicer during the period commencing on January 1, 2015 and ending on December 31, 2015 (or any other shorter period set forth on Schedule I hereto) (the
Reporting Period), and of the Special Servicers performance under the Pooling and Servicing Agreement has been made under my supervision; and
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | To the best of my knowledge, based on such review and using the applicable servicing criteria under Item 1122 of Regulation AB, the Special Servicer has fulfilled all of its obligations under the applicable Pooling and
Servicing Agreement in all material respects throughout the Reporting Period.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



LNR PARTNERS, LLC,a Florida limited liability companyBy:

/s/ Job WarshawJob WarshawPresident


Dated: February 23, 2016





1601 Washington Avenue  Suite
700  Miami Beach, Florida 33139-3164

Telephone: (305) 695-5600  Fax: (305) 695-5601



---

Schedule I

CGCMT 2015-P1

Citigroup Commercial Mortgage Securities Inc.,
Commercial Mortgage Pass-Through Certificates, Series 2015-P1

Citibank, N.A.,

Global Transaction Services

388 Greenwich Street, 14th Floor

New York NY 10013

John Hannon

Citigroup Commercial Mortgage Securities Inc.

390 Greenwich
Street, 5th Floor

New York NY 10013

Paul Vanderslice

Citigroup Commercial Mortgage Securities Inc.

388 Greenwich
Street, 19th Floor

New York NY 10013

Richard Simpson

Citigroup Commercial Mortgage Securities Inc.

388 Greenwich
Street, 17th Floor

New York NY 10013

Ryan M. OConnor

Deutsche Bank National Trust Company

Trust & Agency
Services

1761 E. Saint Andrew Place

Santa Ana CA 92705

Amy McNulty

Park Bridge Lender Services LLC

560 Lexington Avenue, 17th Floor

Att: CGCMT 2015-P1 -
Surveillance Manager

New York NY 10022

David Rodgers

Park Bridge Lender Services LLC

Att: CGCMT 2015-P1

560 Lexington Avenue, 17th Floor

New York NY 10022

Group
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.5960 Cast removal instrument. ( a ) *Identification.* A cast removal instrument is an AC-powered, hand-held device intended to remove a cast from a patient. This generic type of device includes the electric cast cutter and cast vacuum.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 888.9.
[55 FR 48443, Nov. 20, 1990, as amended at 61 FR 1125, Jan. 16, 1996; 66 FR 38816, July 25, 2001]
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________
No. 1D 18

- 0998

_____________________________ A LPHONSO J AMES , S R

. , Appellant,

v.

J ULIE L. J ONES , Secretary, Florida Department o f Corrections
, Appellee.

_____________________ ________

On appeal from the Circuit Court for Jackson County

. Christopher N. Patterson , Judge

. October 4, 2018

P ER C URIAM

.
A FFIRMED

. W OLF , L EWIS , and R OWE , JJ., concur

.

_____________________________ Not final until disposition of any timely and aut horized motion under Fla. R. App. P. 9.330 or 9.331

.

_____________________________2 Alphonso James, Sr., pro se
, Appellant.

Beverly Brewster, Assistant General Counsel, Department of Corrections, Tallahassee
, for Appellee.
§ 1.1015-4 Transfers in part a gift and in part a sale. ( a ) *General rule.* Where a transfer of property is in part a sale and in part a gift, the unadjusted basis of the property in the hands of the transferee is the sum of— ( 1 ) Whichever of the following is the greater: ( i ) The amount paid by the transferee for the property, or
( ii ) The transferor's adjusted basis for the property at the time of the transfer, and
( 2 ) The amount of increase, if any, in basis authorized by section 1015(d) for gift tax paid (see § 1.1015-5). For determining loss, the unadjusted basis of the property in the hands of the transferee shall not be greater than the fair market value of the property at the time of such transfer. For determination of gain or loss of the transferor, see § 1.1001-1(e) and § 1.1011-2. For special rule where there has been a charitable contribution of less than a taxpayer's entire interest in property, see section 170(e)(2) and § 1.170A-4(c).
( b ) *Examples.* The rule of paragraph (a) of this section is illustrated by the following examples:
Example 1. If A transfers property to his son for $30,000, and such property at the time of the transfer has an adjusted basis of $30,000 in A's hands (and a fair market value of $60,000), the unadjusted basis of the property in the hands of the son is $30,000.
Example 2. If A transfers property to his son for $60,000, and such property at the time of transfer has an adjusted basis of $30,000 in A's hands (and a fair market value of $90,000), the unadjusted basis of such property in the hands of the son is $60,000.
Example 3. If A transfers property to his son for $30,000, and such property at the time of transfer has an adjusted basis in A's hands of $60,000 (and a fair market value of $90,000), the unadjusted basis of such property in the hands of the son is $60,000.
Example 4. If A transfers property to his son for $30,000 and such property at the time of transfer has an adjusted basis of $90,000 in A's hands (and a fair market value of $60,000), the unadjusted basis of the property in the hands of the son ins $90,000. However, since the adjusted basis of the property in A's hands at the time of the transfer was greater than the fair market value at that time, for the purpose of determining any loss on a later sale or other disposition of the property by the son its unadjusted basis in his hands is $60,000.
[T.D. 6500, 25 FR 11910, Nov. 26, 1960, as amended by T.D. 6693, 28 FR 12818, Dec. 3, 1963; T.D. 7207, 37 FR 20799, Oct. 5, 1972]
Annual Statement as to Compliance

For the Period of January 1, 2017 to December 31,
2017







COMM 2015-CCRE25







In accordance with Item
1123 of Regulation AB and with the requirements detailed in §10.11 of thePooling and Servicing Agreement (the
“Agreement”) for the above-mentioned CMBS pool, (the “CMBS Pool”),
CWCapital Asset Management LLC (“CWCAM”), in its capacity as Special Servicer, is providing this Officer’s Certificate
with respect to the following:



| | (A) | a review of CWCAM’s activities during the preceding calendar year or portion thereof (the
“Reporting Period”) and of CWCAM’s performance under the Agreement has been made under such officer’s supervision
and;
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (B) | that, to the best of such officer’s knowledge, based on such review, CWCAM has fulfilled
all its obligations under the Agreement in all material respects throughout the Reporting Period.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------





Should you have any questions, please do not hesitate to contact us.



Sincerely,

CWCapital Asset Management LLC







David B. Iannarone

President























7501 Wisconsin Avenue, Suite 500 West, Bethesda, MD 20814
www.cwcapital.com
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3600 Mercury test system. ( a ) *Identification.* A mercury test system is a device intended to measure mercury, a heavy metal, in human specimens. Measurements obtained by this device are used in the diagnosis and treatment of mercury poisoning.
( b ) *Classification.* Class I.
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6887 Spore test strip. ( a ) *Identification.* The spore test strip consists of a carrier or strip with a known number of spores, at least 5 log10 per strip, of known resistance to a particular liquid chemical sterilant in a liquid chemical sterilant processing system. A “no growth” result from the spore test strip after the specified predetermined incubation period indicates that the liquid chemical sterilization process achieved the conditions necessary to kill the specified minimum number of viable spores on the test strip which is 5 log10 spores/strip; it does not confirm the expected full performance of the liquid chemical sterilant processing cycle because full performance is a 6 log10 spore kill in a full liquid chemical sterilization cycle.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) *Spore strip characterization.* ( i ) Population of viable spores on strip shall be a minimum of 5 log10 after physical wash off of spores from the strip by exposure to liquid chemical sterilant in the liquid chemical sterilant processing system, which should be validated over the claimed shelf life.
( ii ) The resistance characteristics of the viable spores on the strip should be defined and be validated over the claimed shelf life.
( iii ) The spore strip description should address the carrier material, how the spores are placed on the carrier, and whether there is any feature that minimizes spore wash off. Bacteriostasis of the spore strip materials should be evaluated.
( iv ) Incubation time for viable spores on the strip should be validated under the specified incubation conditions over the claimed shelf life.
( 2 ) *Simulated Use Testing.* Simulated use testing should demonstrate performance of spore test strip in liquid chemical sterilant/high level disinfectant under worst case in use conditions over the claimed shelf life.
( 3 ) *Labeling.* Labeling should specify appropriate instructions, warnings, cautions, limitations, and information relating to viable spore population, resistance characteristics, and interpretation of a “no growth” result.
[87 FR 8194, Feb. 14, 2022]
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-16-00283-CR

NO. 03-16-00284-CR

Donald Lee Mitchell, Appellant

v.

The State of Texas, Appellee

FROM THE DISTRICT COURT OF BELL COUNTY, 264TH JUDICIAL DISTRICT

NOS. 71726 & 72952, HONORABLE MARTHA J. TRUDO, JUDGE PRESIDING

M E M O R A N D U M O P I N I O N

Appellant Donald Lee Mitchell seeks to appeal a judgment of conviction for

aggravated robbery. See Tex. Penal Code § 29.03. The trial court has certified that (1) these are

plea-bargain cases and Mitchell has no right of appeal, and (2) Mitchell has waived the right

of appeal. Accordingly, we dismiss the appeals for want of jurisdiction. See Tex. R. App. P.

25.2(a)(2), (d).

__________________________________________

Scott K. Field, Justice

Before Justices Puryear, Goodwin, and Field

Dismissed for Want of Jurisdiction

Filed: May 13, 2016

Do Not Publish
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2180 Guaiazulene. ( a ) *Identity.* ( 1 ) The color additive, guaiazulene, is principally 1,4-dimethyl-7-isopropyl-azulene.
( 2 ) Color additive mixtures of guaiazulene for cosmetic use may contain the following diluent: Polyethylene glycol-40 castor oil (PEG-40 castor oil). Saponification No., 60 to 70. Hydroxyl No., 63 to 78. Acid No., 2. Specific gravity, 1.05 to 1.07.
( b ) *Specifications.* Guaiazulene shall conform to the following specifications and shall be free from impurities, other than those named, to the extent that such other impurities may be avoided by good manufacturing practice. Melting point, 30.5 °C to 31.5 °C. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 99 percent.
( c ) *Uses and restrictions.* Guaiazulene may be safely used in externally applied cosmetics in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive for the prescribed use is not necessary for the protection of the public health and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
IB 

House Calendar No. 32 

118TH CONGRESS 

1ST SESSION H. R. 783 

[Report No. 118–163] 

To designate the Department of Energy Integrated Engineering Research 

Center Federal Building located at the Fermi National Accelerator Laboratory in Batavia, Illinois, as the ‘‘Helen Edwards Engineering Research 

Center’’. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 2, 2023 

Mr. FOSTER (for himself and Ms. UNDERWOOD) introduced the following bill; 

which was referred to the Committee on Transportation and Infrastructure 

AUGUST 22, 2023 

Reported from the Committee on Transportation and Infrastructure; referred 

to the House Calendar and ordered to be printed 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 783 RH

A BILL 

To designate the Department of Energy Integrated Engineering Research Center Federal Building located at the 

Fermi National Accelerator Laboratory in Batavia, Illinois, as the ‘‘Helen Edwards Engineering Research Center’’. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 783 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. HELEN EDWARDS ENGINEERING RESEARCH 

4 CENTER. 

5 (a) DESIGNATION.—The Department of Energy Inte6 grated Engineering Research Center Federal Building lo7 cated at the Fermi National Accelerator Laboratory in 

8 Batavia, Illinois, shall be known and designated as the 

9 ‘‘Helen Edwards Engineering Research Center’’. 

10 (b) REFERENCES.—Any reference in a law, map, reg11 ulation, document, paper, or other record of the United 

12 States to the Federal Building referred to in subsection 

13 (a) shall be deemed to be a reference to the ‘‘Helen 

14 Edwards Engineering Research Center’’. 


kjohnson on DSK79L0C42PROD with BILLS
House Calendar No. 32 

118TH CONGRESS 

1ST SESSION H. R. 783 

[Report No. 118–163] 

A BILL 

To designate the Department of Energy Integrated 

Edwards Engineering Research Center’’. oratory in Batavia, Illinois, as the ‘‘Helen located at the Fermi National Accelerator LabEngineering Research Center Federal Building 

AUGUST 22, 2023 

Referred to the House Calendar and ordered to be 

printed 


kjohnson on DSK79L0C42PROD with BILLS
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3050 Spinal interlaminal fixation orthosis. ( a ) *Identification.* A spinal interlaminal fixation orthosis is a device intended to be implanted made of an alloy, such as stainless steel, that consists of various hooks and a posteriorly placed compression or distraction rod. The device is implanted, usually across three adjacent vertebrae, to straighten and immobilize the spine to allow bone grafts to unite and fuse the vertebrae together. The device is used primarily in the treatment of scoliosis (a lateral curvature of the spine), but it also may be used in the treatment of fracture or dislocation of the spine, grades 3 and 4 of spondylolisthesis (a dislocation of the spinal column), and lower back syndrome.
( b ) *Classification.* Class II.
<PAGE>
                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the quarterly report on Form 10-Q of Biopure
Corporation for the period ended July 31, 2004, I, Francis H. Murphy, Chief
Financial Officer, hereby certify, to the best of my knowledge, pursuant to 18
U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:

     1.   the Form 10-Q for the period ended July 31, 2004, fully complies
          with the requirements of section 13(a) or 15(d) of the Securities
          Exchange Act of 1934; and

     2.   the information contained in the Form 10-Q for the period ended July
          31, 2004 fairly presents, in all material respects, the financial
          condition and results of operations of Biopure Corporation.

/s/ Francis H. Murphy
---------------------
Francis H. Murphy
Chief Financial Officer

September 13, 2004
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3970 Interarticular disc prosthesis (interpositional implant). ( a ) *Identification.* An interarticular disc prosthesis (interpositional implant) is a device that is intended to be an interface between the natural articulating surface of the mandibular condyle and glenoid fossa.
( b ) *Classification.* Class III.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 30, 1999, for any interarticular disc prosthesis (interpositional implant) that was in commercial distribution before May 28, 1976, or that has on or before March 30, 1999, been found to be substantially equivalent to an interarticular disc prosthesis (interpositional implant) that was in commercial distribution before May 28, 1976. Any other interarticular disc prosthesis (interpositional implant) shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[59 FR 65478, Dec. 20, 1994, as amended at 63 FR 71746, Dec. 30, 1998]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2780 Hydraulic, pneumatic, or photoelectric plethysmographs. ( a ) *Identification.* A hydraulic, pneumatic, or photoelectric plethysmograph is a device used to estimate blood flow in a region of the body using hydraulic, pneumatic, or photoelectric measurement techniques.
( b ) *Classification.* Class II (performance standards).
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-03-1998
<PERIOD-END>                               OCT-04-1998
<CASH>                                          10,271
<SECURITIES>                                         0
<RECEIVABLES>                                    6,002
<ALLOWANCES>                                        63
<INVENTORY>                                      5,351
<CURRENT-ASSETS>                                27,857
<PP&E>                                         336,531
<DEPRECIATION>                                 125,663
<TOTAL-ASSETS>                                 244,428
<CURRENT-LIABILITIES>                           42,751
<BONDS>                                         15,289
<COMMON>                                         2,226
<PREFERRED-MANDATORY>                            2,287
<PREFERRED>                                          0
<OTHER-SE>                                     176,511
<TOTAL-LIABILITY-AND-EQUITY>                   244,428
<SALES>                                        289,092
<TOTAL-REVENUES>                               292,056
<CGS>                                          133,090
<TOTAL-COSTS>                                  246,765
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,019
<INCOME-PRETAX>                                 45,291
<INCOME-TAX>                                    17,594
<INCOME-CONTINUING>                             27,697
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    27,697
<EPS-BASIC>                                     1.52
<EPS-DILUTED>                                     1.48


</TABLE>
#### § 510.206 Review of information supporting actions to establish or amend an import tolerance.

In establishing or amending an import tolerance, the Commissioner shall rely on data sufficient to demonstrate that a proposed tolerance is safe based on similar food safety criteria used by the Commissioner to establish tolerances for applications for new animal drugs filed under section 512(b)(1) of the Federal Food, Drug, and Cosmetic Act. In establishing or amending an import tolerance, the Commissioner will give appropriate consideration to the anticipated residue concentrations and conditions of use of the new animal drug specified.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.3750 External prosthesis adhesive. ( a ) *Identification.* An external prosthesis adhesive is a silicone-type adhesive intended to be used to fasten to the body an external aesthetic restoration prosthesis, such as an artificial nose.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38802, July 25, 2001]
IN THE

TENTH COURT OF APPEALS

No. 10-21-00220-CV

IN RE JOY'E HUDSON

Original Proceeding

From the 170th District Court

McLennan County, Texas

Trial Court No. 2019-1911-4

MEMORANDUM OPINION

Relator’s Petition for Writ of Mandamus, filed on September 3, 2021, is denied.

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Justice Johnson, and 

Justice Smith

Petition denied

Opinion delivered and filed September 15, 2021

[OT06]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5715 Plasminogen immunological test system. ( a ) *Identification.* A plasminogen immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the plasminogen (an inactive substance from which plasmin, a blood-clotting factor, is formed) in serum, other body fluids, and tissues. Measurement of plasminogen levels may aid in the diagnosis of fibrinolytic (blood-clotting) disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2313, Jan. 14, 2000]